Burns-Cox C J, Chandrasekhar K P, Ikram H, Peirce T H, Pilcher J, Quinlan C D, Rees J R
Br Med J. 1971 Dec 4;4(5787):586-8. doi: 10.1136/bmj.4.5787.586.
This paper reports a double-blind trial of a new antianginal drug, perhexiline. Fifty-five patients suffering from angina pectoris were studied for periods of 12 or 24 weeks in a cross-over comparison against a placebo in four centres in the United Kingdom and Ireland. Perhexiline was effective in most patients as judged by reducing the number of anginal attacks in 84% and the consumption of glyceryl trinitrate tablets in 64%. The major side effect, dizziness, noted in one-third of the patients, may be dose/body-weight related. Perhexiline is a valuable new agent for the treatment of patients with angina, especially those who do not respond to other antianginal agents.
本文报道了一种新型抗心绞痛药物哌克昔林的双盲试验。在英国和爱尔兰的四个中心,对55名心绞痛患者进行了为期12周或24周的研究,采用交叉对照安慰剂的方法。根据减少心绞痛发作次数(84%)和硝酸甘油片消耗量(64%)来判断,哌克昔林对大多数患者有效。三分之一的患者出现的主要副作用头晕,可能与剂量/体重有关。哌克昔林是治疗心绞痛患者的一种有价值的新药,尤其适用于对其他抗心绞痛药物无反应的患者。